- Press Release
- Non-Invasive Prenatal Testing Market to Reach US$ 1,936.4 Million by 2027
Non-Invasive Prenatal Testing Market to Reach US$ 1,936.4 Million by 2027 - Coherent Market Insights
Published On : Oct 12, 2020
Non-invasive prenatal testing (NIPT) is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome.
Statistics:
The global non-invasive prenatal testing market is estimated to account for US$ 971.9 Mn in terms of value by the end of 2020.
Global Non-Invasive Prenatal Testing Market: Drivers
Launch and approval of new products is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, in November 2019, F. Hoffmann-La Roche Ltd. received approval from Health Canada for its non-invasive prenatal test, Harmony Test. The Harmony Test is designed to screen the trisomy 21 (Down syndrome) and other common fetal aneuploidies.
Global Non-Invasive Prenatal Testing Market: Opportunities
Inclusion in clinical practice guidelines is expected to offer lucrative growth opportunities for players in the global non-invasive prenatal testing market. Obtaining recommendations and inclusion of NIPT testing within clinical guidelines and frameworks is a major step in being able to educate obstetricians and increasing adoption of these tests.
Global Non Non-Invasive Prenatal Testing Market: Restraints
Abortion of pregnancy based on test results is expected to hinder growth of the global non-invasive prenatal testing market. Several cases have been identified where women have opted for abortions based on a positive screening test result due to possibility of birth with genetic defects.
Key Takeaways:
The global non-invasive prenatal testing market was estimated at US$ 971.9 Mn in 2020 and is forecast to reach a value of US$ 1,936.4 Mn by 2027 at a CAGR of 10.3% between 2020 and 2027. Launch and approval of new products is expected to propel growth of the global non-invasive prenatal testing market over the forecast period.
Panel 1 Test segment held dominant position in the global non-invasive prenatal testing market in 2019, accounting for 57.9% share in terms of value, increasing prevalence of chromosomal disorders is anticipated to propel the segment growth during the forecast period.
Market Trends
Increasing number of women smoking cigarettes is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, according to the Centers for Disease Control and Prevention, in 2018, nearly 14 of every 100 U.S. adults aged 18 years or older smoked cigarettes. Men were more likely to be current cigarette smokers than women. About 12 of every 100 adult women (12.0%) smoked cigarettes in 2018.
Major players in the global non-invasive prenatal testing market are focused on gaining extended coverage for its products to enhance their market share. For instance, in October 2020, Natera, Inc. announced that Centene, a major healthcare insurance company, has extended coverage of the Panorama non-invasive prenatal test (NIPT) to all pregnant women, including twin pregnancies, representing 24 million additional covered lives.
Regulations
U.S.
Global Non-Invasive Prenatal Testing Market: Competitive Landscape
Major players operating in the global non-invasive prenatal testing market include, Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc., LifeCodexx AG, Natera, Inc., Sequenom, Inc., Natera, Inc., Axia Women’s Health, Eluthia, BillionToOne, Inc., and Quest Diagnostics Incorporated.
To know the latest trends and insights related to global Non-Invasive Prenatal Testing Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/non-invasive-prenatal-testing-nipt-market-579
Global Non-Invasive Prenatal Testing Market: Key Developments
Major players in the global non-invasive prenatal testing market are focused on launching new products to expand their product portfolio. For instance, in October 2019, BillionToOne, Inc., a diagnostics company, and Eluthia, a Europe-based genetic diagnostic tests provider, announced the launch of UNITY test, a non-invasive prenatal test, in the European region.
Segmentation
Scope of the report
Joining thousands of companies around the world committed to making the Excellent Business Solutions.